- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
HIMA urges firms to use third-party review
The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.Last month HIMA passed a
The Health Industry Manufacturers Association is urging medical device companies to take increasing advantage of a third-party review system within the Food and Drug Administration to gain quicker approval for their products.
Last month HIMA passed a resolution reminding companies to use the third-party review system. HIMA represents more than 800 manufacturers of medical devices, diagnostic products, and medical information systems.
The Food and Drug Administration Modernization Act, passed three years ago, devised the third-party system in response to a growing backlog of FDA applications and a dearth of personnel to complete the reviews. The act created a group of scientific and industry experts qualified to grant FDA approval for medical devices, said Linda Ruckel, HIMA spokeswoman.
HIMA members may be hesitant to use the third-party review system for product approval because they arent used to it, Ruckel said.
We believe its a good thing. A lot of times (members) will go for the old tried and true way rather than a new format, Ruckel said. We know its out there and we want to encourage (companies) to use it more.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
